AC Immune S.A.ACIUNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank41
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P41
Within normal range
vs 3Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -17.58% |
| Q2 2025 | 17.10% |
| Q1 2025 | -417.09% |
| Q4 2024 | 141.96% |
| Q3 2024 | -119.37% |
| Q2 2024 | 7031.54% |
| Q1 2024 | 106.32% |
| Q4 2023 | -21.74% |
| Q3 2023 | 5.78% |
| Q2 2023 | 15.98% |
| Q1 2023 | 3.48% |
| Q4 2022 | -28.59% |
| Q3 2022 | 30.51% |
| Q2 2022 | 15.82% |
| Q1 2022 | -29.81% |
| Q4 2021 | -22.96% |
| Q3 2021 | 9.51% |
| Q2 2021 | 7.59% |
| Q1 2021 | 10.45% |
| Q4 2020 | -24.15% |
| Q3 2020 | -4.89% |
| Q2 2020 | -53.50% |
| Q1 2020 | 23.99% |
| Q4 2019 | -174.90% |
| Q3 2019 | 213.17% |
| Q2 2019 | -122.79% |
| Q1 2019 | 661.28% |
| Q4 2018 | 0.72% |
| Q3 2018 | -65.98% |
| Q2 2018 | 46.55% |
| Q1 2018 | -309.89% |
| Q4 2017 | 184.33% |
| Q3 2017 | 16.47% |
| Q2 2017 | 24.03% |
| Q1 2017 | -71.78% |
| Q4 2016 | -181.64% |
| Q3 2016 | 1654.45% |
| Q2 2016 | 106.28% |
| Q1 2016 | -37.85% |
| Q4 2015 | -116.59% |